Bayer AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bayer AG with three other
pharmaceutical manufacturers in Europe:
sales of 48.29 billion Swiss Francs [US$53.19 billion]
of which 78%
was Innovative Medicines),
(37.63 billion Euros [US$44.85 billion]
of which 68%
was Pharmaceuticals), and
based in UNITED KINGDOM
(£33.75 billion [US$45.19 billion]
of which 52%
Bayer AG reported sales of 43.55 billion Euro (US$51.90 billion)
December of 2019.
increase of 10.0%
versus 2018, when the company's sales were 39.59 billion Euro.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Bayer AG had sales
of 42.24 billion Euro.
Sales of Cropscience saw an increase
that was more than double the company's growth rate: sales were up
39.0% in 2019, from
14.27 billion Euro to 19.83 billion Euro.
Not all segments of Bayer AG experienced an increase in sales in 2019:
sales of All Other Segments fell 82.7% to 277.00 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).
Bayer AG also experienced decreases in sales in
Reconciliations (down 33.3% to 12.00 million Euro)